AxoGen (NASDAQ:AXGN) Reaches New 1-Year High – Time to Buy?

AxoGen, Inc. (NASDAQ:AXGN)’s stock price reached a new 52-week high during trading on Thursday . The stock traded as high as $19.03 and last traded at $18.89, with a volume of 457510 shares trading hands. The stock had previously closed at $18.97.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th.

AxoGen Price Performance

The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67. The company has a 50 day moving average of $15.40 and a 200-day moving average of $13.30. The firm has a market capitalization of $831.35 million, a P/E ratio of -59.03 and a beta of 1.01.

Institutional Investors Weigh In On AxoGen

Institutional investors have recently modified their holdings of the business. Sentry Investment Management LLC raised its stake in AxoGen by 9.3% in the 3rd quarter. Sentry Investment Management LLC now owns 17,368 shares of the medical equipment provider’s stock worth $243,000 after purchasing an additional 1,483 shares in the last quarter. Quest Partners LLC boosted its stake in shares of AxoGen by 23,066.7% in the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 2,076 shares during the period. Rhumbline Advisers grew its position in AxoGen by 6.2% during the second quarter. Rhumbline Advisers now owns 58,157 shares of the medical equipment provider’s stock worth $421,000 after buying an additional 3,380 shares in the last quarter. nVerses Capital LLC bought a new position in AxoGen during the 3rd quarter worth $56,000. Finally, SG Americas Securities LLC raised its holdings in AxoGen by 34.4% in the 4th quarter. SG Americas Securities LLC now owns 21,763 shares of the medical equipment provider’s stock valued at $359,000 after acquiring an additional 5,576 shares in the last quarter. Institutional investors own 80.29% of the company’s stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.